Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for ABT and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for ABT and 80,000+ other tickers.
See exactly how ABT's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for ABT and 80,000+ other tickers.
Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm…
Ameritas Advisory Services LLC grew its holdings in shares of Abbott Laboratories (NYSE: ABT) by 76.8% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 15,622 shares of the healthcare product maker's stock after purchasing an additional 6,788 shares during the quarter.
Investors interested in Medical - Products stocks are likely familiar with Envista (NVST) and Abbott (ABT). But which of these two companies is the best option for those looking for undervalued stocks?
FDA approval for TactiFlex Duo expands ABT's AFib ablation portfolio with dual PFA and RF energy options, supporting broader U.S. adoption.
Dividend seekers can hardly go wrong with these companies.
Abbott (ABT) concluded the recent trading session at $105.52, signifying a -2.59% move from its prior day's close.